Capital One Financial Corp. vs DexCom, Inc. — how do they compare? Capital One Financial Corp. trades at $221.47 (market cap $134.45B), while DexCom, Inc. trades at $90.53 (market cap $33.79B). The key difference: Capital One Financial Corp. is far larger — about 4× DexCom, Inc.'s market cap, and Capital One Financial Corp. pays a 1.46% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| COF | DXCM | |
|---|---|---|
Market Cap | $134.45B | $33.79B |
Sector | Financials | Health |
52-Week High | $257.94 | $89.53 |
52-Week Low | $176.10 | $54.84 |
Dividend Yield | 1.46% | — |
Enterprise Value | — | $33.24B |
Signals from Pluang's Aura AI — not financial advice
Capital One Financial (COF) trades at $221.20, up 1.02% today, with a bullish technical signal from moving averages but overbought RSI readings near 77. The stock shows strong fundamentals with a P/E of 12.07 and net income margin of 16.96% for 2026, supported by robust Q2 2026 earnings beating estimates. Recent news highlights the Discover integration progress and a 20-year arena naming rights extension, reinforcing brand commitment.
Outlook is positive with a consensus price target of $251.60, implying 14% upside, driven by earnings growth and synergy capture from Discover. Key risks include integration execution, credit loss provisions, and economic sensitivity. The bullish analyst consensus (63% Buy) and institutional holdings suggest confidence in continued performance, though overbought conditions may prompt near-term volatility.
DXCM trades at $90.23, up 2.94% today and near its 52-week high, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating EPS estimates with $0.70 versus $0.61 expected, and raised full-year guidance. Revenue growth remains robust at 13% year-over-year, supported by G7 system adoption and international expansion. Profit margins improved, with net income margin reaching 20.12% in 2025. Analyst sentiment is overwhelmingly positive, with 80% buy ratings.
The outlook for DXCM is favorable due to sustained demand for continuous glucose monitors and strategic initiatives like 'Road to 100'. Key risks include competitive pressures, regulatory scrutiny, and valuation multiples above industry averages. The stock's current price is slightly above the consensus target of $88.65, suggesting near-term consolidation may occur before further upside.
Trailing returns across standard periods
Latest headlines on both assets
Capital One is a diversified financial services holding company headquartered in McLean, Virginia. Originally a spinoff of Signet Financial's credit card division in 1994, the company is now primarily involved in credit card lending, auto loans, and commercial lending.
Read more on COF →Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →